KINS CARE & RESEARCH FOUNDATION PVT LTD

(Department of Laboratory Services)

Proficiency Testing Action Report Form

ate: 06,01,7824 cceptable Criteria: SDI Range	e least		
fithin -1.00 to +1.00	Excellent.	•	
Vithin ±1.01 to ±2.00	Good.		
Within ±2.01 to ±2.99	Accept with caution. Warning Signal		
Beyond ±3.0	Unacceptable performance. Action 9	Signal.	
EQAS FINDINGS: All prosound Veney exert	grove Mish. e "Total Protien!"		
COULD THIS ERROR AFFE	ECT PATIENT RESULTS?		Y/N
COULD THIS ERROR AFFE	ECT PATIENT RESULTS?	new.	

EQAS CORRECTIVE ACTION FORM

Name of the lab: KCRK	_EQAS Program:
Department: Wero Array	Cycle #: 6-losury 2024
Analyte: Total Brehim	Lab Result: 4.46
Z-score: 3.25	Peer Mean:
I. Sample Receipt:	
 Was the kit received in good condition? Was the correct program/cycle received? Was the kit stored at the proper temperature follows: 	(Yes/No/NA) (Yes/No/NA) owing receipt? (Yes/No/NA)
II. Sample Preparation:	
 Was the correct reconstitution instruction follow Was a volumetric Class A (or calibrated) pipette 	ed? (Yes/No/NA) used for reconstitution? (Yes/No/NA)
 Was distilled or deionized water used for recons Was the sample mixed according to the package 	insert prior to testing? (Yes/No/NA) (Yes/No/NA)
III. Sample Processing:	
 Was the correct sample number tested? Was the sample at room temperature? Was the person running the test current in their to the was the affected test run within the stability class. 	(Yes/No/NA) (Yes/No/NA) (Yes/No/NA) im listed in the package insert? (Yes/No/NA)
IV. Reporting Results:	
 Was the test configuration correct (instrument, and the results been reported correctly (match and the correct unit reported? Was the decimal symbol placed correctly when and the reported result within the instrument's and the calculation of the reported result done 	reported? (Yes/No/NA) (Yes/No/NA) (Yes/No/NA) (Yes/No/NA) (Yes/No/NA)
V. Internal QC:	
 Was IQC within an acceptable range on the day Where there any shifts or trends in IQC just be 	that the EQAS sample was run?(Yes/No/NA) fore/after the EQAS sample was run?
*	(Yes/No/NA)
VI. Calibration:	
Controlled copy	Page 1

– Was the	e last calibration acceptable? e last calibration within the manufacturers recommended dating?	(Yes/No/NA) (Yes/No/NA)
VII.	Reagent:	Jesoi I Voi IVA)
 Was the 	test reagent stored correctly? test reagent properly prepared? test reagent within manufacturer's dating?	(Yes/No/NA) (Yes/No/NA) (Yes/No/NA)
VIII.	Instrument:	(1001101111)
- Was the	ly maintenance performed on the day that the EQAS sample was run? person performing maintenance current on training? instrument operating correctly on the day the sample was tested? lab environment acceptable for the instrument?	(Yes/No/NA) (Yes/No/NA) (Yes/No/NA) (Yes/No/NA)
IX.	Sample Retest:	
Was theIf yes, w	EQAS sample retested following receipt of EQAS sample report? vas the result within acceptable limits for the EQAS sample?	(Yes/No/NA) (Yes/No/NA)
X.	EQAS Evaluation:	
 Inapproprint Instrument 	priate peer group or comparator priate evaluation criteria, e.g. narrow limits due to use of a precise method. (Consider use of the Quality Specification Report) se of Problem: Total Robbin BUSS Value Form on or or A robbin evaluation criteria, e.g. narrow limits due to use of a precise method.	(Yes/No/NA)
Corrective		
Reviewed	Reagest toeglieen & D. Never promonting. By: OHALT MAGER PUTILID.	10 Jus
Controlled (KINSCAME & RESEARCH PORT, DARJEELING SILISURI, DIST, DARJEELING	Page 2



CHRISTIAN MEDICAL COLLEGE

DEPARTMENT OF CLINICAL BIOCHEMISTRY

CMC EXTERNAL QUALITY ASSURANCE SCHEME MONTHLY SUMMARY REPORT - FEBRUARY 2024



Lab Name

KINS CARE & RESEARCH FOUNDATION

Lab No

4531

Constituent Group

Chemistry I

Date of Result Entered :

20/02/2024

PT item

Lyophilized human serum based

Date of Report Published :

05/03/2024

SI.No	Analyte	Method / Principle Name		No of Participant	ts AV	Par	ticipant:	loui		
2	GLUCOSE	GOD-POD	Any Analyser (Automation) Semi Automation)	1176	251.2		+	050		e
-06/7¢	UREA	Urease UV / GLDF	Beckman AU480/680/5800/DXC700AU	176	64.0		3.22	mg/dl 64		-
3	CREATININE	Enzymatic Colorimetric	Beckman AU480/680/5800/DXC700AU	39	5.76	1.00	-	mg/dL 5.27	-0.02	0.
4	T.BILIRUBIN	Diazonium salt (Colorimetric) / Jendrassik	Beckman AU480/680/5800/DXC700AU	121			0.33	mg/dL	-1.47	0.
5	T-PROTEIN	Biuret - Colorimetric	Beckman		3.21	4.73	0.15	3.19 mg/dL	-0.13	0.
6	ALBUMIN	BCG - colorimetric	AU480/680/5800/DXC700AU Beckman	169	5.00	3.32	0.17	4.46 g/dL	-3.25	0.0
7	CALCIUM	Arsenazo III	Beckman	173	3.16	3.49	0.11	2.99 g/dL	-1.55	0.0
8	PHOSPHORUS	Molybdate UV / Phosphomolybdate	AU480/680/5800/DXC700AU Beckman	168	10.68	3.55	0.38	10.9 mg/dL	0.58	0.0
		complex Enzymatic /	AU480/680/5800/DXC700AU	130	3.25	6.61	0.22	3.36 mg/dL	0.51	0.0
	URIC ACID	Uricase Colorimetric	Beckman AU480/680/5800/DXC700AU	168	7.21	4.23	0.30	6.91	-0.98	0.0
10 (CHOLESTEROL		Beckman AU480/680/5800/DXC700AU	173	112.23	4.00	100	mg/dL	-0.98	0.0
11 7	RIGLYCERIDE	GPO-PAP / Enzymatic Colorimetric / End Point	Beckman AU480/680/5800/DXC700AU	171	187.80		5.56 12.18	mg/dL 162.35	0.14	8.0
12 H	IDL	Direct method /	Beckman AU480/680/5800/DXC700AU	158	25.43	5.54	1.41	mg/dL 26	-2.09	1.8
13 S	ODIUM	ISE - Indirect	Beckman	99	400.40			mg/dL 131.7	0.40	0.22
14 P	OTASSIUM	ISF - Indirect	AU480/680/5800/DXC700AU Beckman AU480/680/5800/DXC700AU	99	129.43	1.29		mmol/L 5.09	1.36	0.34
15 C		ISE - Indirect	Beckman AU480/680/5800/DXC700AU	94	5.00 94.27	1.78		mmol/L 94	1.01	0.02
16 AS	21	Without PLP /P 5	Beckman			2.04	1.93	mmol/L	-0.14	0.40
17 AL		UV kinetic(with &	AU480/680/5800/DXC700AU	167	76.08	5.76	4.38	79.2 U/L	0.71	0.68
	F		Beckman AU480/680/5800/DXC700AU	165	96.88	6.56	6.35	96.7 U/L	-0.03 0	0.99
8 AL		PNP AMP kinetic	Beckman AU480/680/5800/DXC700AU	163	90.94	9.63	8.75	82 U/L	-	
9 AN	TYLASE C	Colorimetric /	Beckman MU480/680/5800/DXC700AU	41	68.11 1		10.95	50.6		1.37
0 IRO	ON 1	PTZ (Tripyridyl-S-	Beckman .U480/680/5800/DXC700AU		19.50			U/L 109.6	-1.60 3	.42

u* - Method of Uncertainty

Z-Score	u* - Meth
	Interpretation
$ z \le 2.0$ $ z \le 3.0$	Acceptable
s://home.cmcvellore.ac.in/clingc/\/iow\Moath\	Warning Signal



CHRISTIAN MEDICAL COLLEGE

DEPARTMENT OF CLINICAL BIOCHEMISTRY CMC EXTERNAL QUALITY ASSURANCE SCHEME MONTHLY SUMMARY REPORT - FEBRUARY 2024



Lab Name

KINS CARE & RESEARCH FOUNDATION

Lab No

4531

Constituent Group

HbA1c

Date of Result Entered :

20/02/2024

PT item

Lyophilized human whole blood based

Date of Report Published:

05/03/2024

SI.No	Analyte	Method / Principle Name	Analyzer Name	Analyzer Name No of Participants		cipants	Your 7		1	
		Turbidimetric		Participants		CV	SDPA	Value	Score	u*
1	HbA1c	Inhibition Immunoassay	Beckman AU480/680/5800/DXC700AU	39	6.90	7.23	0.50	6.8 %	-0.20	0.16

u* - Method of Uncertainty

Z-Score		
IzI ≤ 2,0	Interpretation	
	Acceptable	
2.0 < z < 3.0	Warning Signal	
z ≥ 3.0		
	Unacceptable (action Signal)	

LAB ADDRESS:

KINS CARE & RESEARCH FOUNDATION
JHANKAR MORE, Ist FLOOR, GOLDEN HEIGHTS BUILDING, BURDWAN ROAD
SILIGURI
WEST BENGAL734005

Coordinator Contact Details: Email:clinqc@cmcvellore.ac.in Contact Number: 0416-2283102 Panela Christudess

Dr. Pamela Christudoss CMC EQAS Coordinator Christian Medical College, Vellore

Homogeneity and Stability of the sample is passed.

Data in CMC EQAS reports is confidential

CMC EQAS does not sub contract any components

******** End of Report *******



CHRISTIAN MEDICAL COLLEGE

DEPARTMENT OF CLINICAL BIOCHEMISTRY

CMC EXTERNAL QUALITY ASSURANCE SCHEME MONTHLY SUMMARY REPORT - FEBRUARY 2024



Lab Name

KINS CARE & RESEARCH FOUNDATION

Lab No

4531

Constituent Group

Thyroid Hormones & Cortisol

Date of Result Entered :

20/02/2024

PT item

Lyophilized human serum based

Date of Report Published :

05/03/2024

SI.No	Analyte	Method / Principle Name	Analyzer Name	No of	AV	Parti	cipants	Your	Z	i –
	TOTAL	CLIA-		Participants		CV	SDPA	Value	Score	u*
_	THYROXINE	Chemiluminescence immunoassay / CMIA	Beckman Acces2, Acces2I, DXI600, DXI800	169	10.51	15.76	1.66	13.13	1.58	0.2
	FREE THYROXINE	CLIA- Chemiluminescence immunoassay / CMIA	Beckman Acces2, Acces2l	140	2.79	10.62	0.30	ug/dL 2.86		-
3	TSH	CLIA-	DXI600, DXI800 Beckman			10.02	0.50	ng/dL	0.24	0.0
		Chemiluminescence	Acces2, Acces2l, DXI600, DXI800	190	10.85	6.39	0.69	10.6 uIU/mL	-0.36	0.10
4	TOTAL T3	CLIA- Chemiluminescence immunoassay / CMIA	Beckman Acces2, Acces2I, DXI600, DXI800	159	137.74	11.05	15.22	127 ng/dL	-0.71	2.41

u* - Method of Uncertainty

Z-Score				
	Interpretation			
IzI ≤ 2.0				
2.0 < z < 3.0	Acceptable			
z ≥ 3.0	Warning Signal			
121 2 3.0	Unacceptable (action Signal)			

LAB ADDRESS:

KINS CARE & RESEARCH FOUNDATION JHANKAR MORE, Ist FLOOR, GOLDEN HEIGHTS BUILDING, BURDWAN ROAD SILIGURI WEST BENGAL734005

> Coordinator Contact Details: Email:clinqc@cmcvellore.ac.in Contact Number: 0416-2283102

Panela Christudoss

Dr. Pamela Christudoss CMC EQAS Coordinator Christian Medical College, Vellore

Homogeneity and Stability of the sample is passed.

Data in CMC EQAS reports is confidential

CMC EQAS does not sub contract any components

******** End of Report *******